Floatz logo

METHOXIFLURANE

Chronic Rhinosinusitis (CRS)

St. Paul's Hospital, CanadaSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Chronic Rhinosinusitis (CRS) cohort.

Asset / SponsorPhaseRating
Cipralex
University of Washington
Phase 4BB
Omalizumab
University of California, San Francisco
Phase 4BB
S-Ketamine
The Second People's Hospital of Huai'an
Phase 1/2CC
ELEXACAFTOR
University of California, Los Angeles
D
Tezacaftor
University of California, Los Angeles
D

View all 9 →

Same molecule, other indications

METHOXIFLURANE is also rated in:

cancerDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →